- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Combimist L Inhaler
Combimist L Inhaler is a combination inhaled bronchodilator containing levosalbutamol (a short‑acting beta₂‑agonist) and ipratropium bromide (a short‑acting anticholinergic). It is indicated for the relief of bronchospasm in patients with chronic obstructive pulmonary disease (COPD) and for the management of reversible airflow obstruction in conditions where a dual bronchodilator approach is required. Levosalbutamol relaxes airway smooth muscle by stimulating beta₂‑adrenergic receptors, while ipratropium blocks M3 muscarinic receptors, reducing vagally mediated bronchoconstriction and mucus secretion. The combination provides rapid and effective bronchodilation. Combimist L is intended for as‑needed use and is not a replacement for maintenance controller therapy.
Usual adult dose: For acute bronchospasm, the recommended dose is 1 to 2 inhalations (providing 50 mcg levosalbutamol and 20 mcg ipratropium per actuation) as needed, up to 3 to 4 times daily. The maximum total daily dose is 8 inhalations (400 mcg levosalbutamol and 160 mcg ipratropium) in 24 hours. Patients should be instructed to shake the canister well before each use and to prime the inhaler before first use or after a period of non‑use. If symptoms persist, worsen, or require more frequent doses, immediate medical attention is required.
Dosage form: Pressurized metered‑dose aerosol inhaler (HFA) delivering 50 mcg of levosalbutamol (as sulfate) and 20 mcg of ipratropium bromide per actuation. Each canister contains 200 metered actuations.
Onset of action: Bronchodilation begins within 5 to 15 minutes after inhalation, with peak improvement in lung function occurring within 30 to 60 minutes.
Duration of action: The bronchodilator effect lasts approximately 4 to 6 hours, allowing for administration up to 4 times daily.
Alcohol recommendation: There is no known direct interaction between inhaled levosalbutamol/ipratropium and alcohol. However, excessive alcohol consumption may worsen underlying respiratory conditions and increase the risk of respiratory depression. Moderation is advisable.
Most common side effects: Dry mouth, tremor, nervousness, headache, tachycardia, palpitations, throat irritation, cough, and constipation. Dry mouth is a known anticholinergic effect; rinsing the mouth after use may help. The beta₂‑agonist component may cause dose‑related tremor and palpitations, which generally diminish with continued use. Patients with narrow‑angle glaucoma, prostatic hyperplasia, or bladder‑neck obstruction should use with caution due to the anticholinergic component. Contact of the spray with the eyes should be avoided as it may cause pupil dilation and blurred vision. Overuse of the inhaler may indicate worsening of the underlying disease; a healthcare professional should be consulted promptly if the need for rescue doses increases. Combimist L is not a maintenance controller; all patients with persistent COPD should be assessed for appropriate long‑acting bronchodilator or anti‑inflammatory therapy.
Would you like to try Combimist L Inhaler without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
